The fact
The French biotech, specializing in innovative therapies, is going through a critical phase.
Investors speculate on a rebound or restructuring.
Click the link to read an article on the topic:
The French biotech, specializing in innovative therapies, is going through a critical phase.
Investors speculate on a rebound or restructuring.